Dermata Therapeutics reports Q1 EPS (45c) vs. ($7.06) last year

“It was an exciting quarter for our team to announce positive topline results of the XYNGARI Phase 3 STAR-1 trial for the treatment of acne, which achieved statistically significant results of its three co-primary endpoints at all time points,” commented Gerry Proehl, Dermata’s Chairman, President, and Chief Executive Officer. “Our team has spent many years working with this product and knew it had strong potential as a treatment for acne and we are happy to see that hard work has paid off with such positive results. We believe the consistent results from our previous clinical studies and this Phase 3 trial derisks the planned second Phase 3 trial and well positions XYNGARI to potentially be the first once-weekly, natural, topical treatment for moderate-to-severe acne, if approved. We are also excited to have partnered with Revance to study DMT410 with DAXXIFY for the topical treatment of axillary hyperhidrosis,” continued Mr. Proehl. “We see a lot of potential uses for our DMT410 program and studying it in a Phase 2 study with a long-lasting botulinum toxin, like DAXXIFY, could provide us with the data needed to show the clinical efficacy of DMT410 aiding in the topical delivery of a botulinum toxin,” concluded Mr. Proehl.